Vistagen Therapeutics (VTGN) Shares Outstanding (2012 - 2026)

Vistagen Therapeutics has reported Shares Outstanding (Entity) for 15 years, with the latest figure at $39.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 36.63% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.6 million (up 36.63% YoY) and the FY2026 annual result came in at $39.6 million, up 36.63% from the prior year.
• Shares Outstanding (Entity) steadied at $39.6 million in Q1 2026 per VTGN's latest filing, from $39.6 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $39.6 million in Q4 2025 and troughed at $6.9 million in Q1 2022.
• A 5-year average of $21.2 million and a median of $27.0 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) climbed 0.2% in 2022, then soared 291.68% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $6.9 million in 2022, then jumped by 291.68% to $27.0 million in 2023, then gained by 4.78% to $28.3 million in 2024, then jumped by 39.91% to $39.6 million in 2025, then changed by 0.0% to $39.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $39.6 million, $39.6 million, and $38.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.